Global News and Digital Insights
for the Healthcare Industry

Promising drug candidate offers new hope for rare eye infection – Acanthamoeba Keratitis

A drug candidate developed through collaborative research between UCL and Moorfields Eye Hospital is proving highly effective in treating Acanthamoeba keratitis (AK), a rare and sight-threatening eye infection. The drug, a low concentration of polihexanide (PHMB 0.08%), is being studied as part of a clinical trial in partnership with SIFI S.p.A. AK, a corneal infection, can cause extreme pain and light sensitivity, affecting contact lens wearers disproportionately. The trial, involving 127 individuals across Europe, showed an 87% medical cure rate for AK using the high-concentration polihexanide, a remarkable success. The drug is particularly advantageous when administered as monotherapy, and the research may lead to regulatory approvals for its use in Europe, the UK, and the US, offering hope to AK patients.

Read more from Newsmedical
Facebook
Twitter
LinkedIn